![](https://aerobe.com/wp-content/uploads/2024/04/unnamed.png)
Webinar : Introducing TMS for depression on 4th April 2024
Samuel Jacobs and Dr. Claus Mathiesen will explore the past, present and future of Transcranial Magnetic Stimulation. Don’t miss this insightful session!
Samuel Jacobs and Dr. Claus Mathiesen will explore the past, present and future of Transcranial Magnetic Stimulation. Don’t miss this insightful session!
Repetitive transcranial magnetic stimulation (rTMS) noninvasively stimulates the brain using electromagnetic pulses, and has been FDA- approved for treatment resistant depression (TRD) (O’Reardon et al.,
In this webinar we will provide an overview of the history as well as the basic principles of TMS. Following the introduction will be our
Currently, there are mixed research findings on the topic of whether advanced age is a poor prognostic indicator for rTMS. A thorough retrospective chart analysis
The study objective was to investigate the predictive value of functional connectivity changes induced by acute repetitive transcranial magnetic stimulation (rTMS) for clinical response in
Cocaine use disorder (CUD) is a global health issue with no effective treatment. Repetitive Transcranial Magnetic Stimulation (rTMS) is a recently proposed therapy for CUD.
Abstract Introduction: Chronic migraine is a disease of altered cortical excitability. Repetitive transcranial magnetic stimulation provides a novel non-invasive method to target the nociceptive circuits in
FDA has cleared MagVenture TMS Therapy® for adjunct treatment of Obsessive-Compulsive Disorder (OCD). This marks MagVenture’s second indication in the US. MagVenture TMS Therapy is
We provide solutions for healthcare and research. We distribute medical equipment, provide scientific expertise and support.
© 2023 Aerobe. All Rights Reserved Terms & Conditions | Privacy Policy